Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company’s main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.